Bibliography
- Castelli WP , GarrisonRJ, WilsonPWFet al..: Incidence of coronary artery disease and high density lipoprotein cholesterol levels. The Framingham Study. JAMA 256, 2835–2838 (1986).
- Gordon DJ , ProbstfieldJL, GarrisonRJet al.: High density lipoprotein cholesterol and cardiovascular disease. Four prospective cardiovascular studies. Circulation 79, 8–15 (1989).
- Spady DK : Reverse Cholesterol transport and atherosclerosis regression.Circulation 100, 576- 578 (1999).
- Dattilo AM , Kris-EthertonPM: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis.Am. J. Clin. Nutr. 56, 320–328 (1992).
- Moffatt RJ : Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol.Atherosclerosis 74, 85–89 (1988).
- Kokkinos PF , HollandJC, NarayanPet al..: Miles run per week and high-density lipoprotein cholesterol levels in healthy, middle-aged men. A dose–response relationship. Arch. Intern. Med. 155, 415–420 (1995).
- Thornton J , SymesC, HeatonK: Moderate alcohol intake reduces bile cholesterol saturation and raises HDL-C.Lancet 8354, 819–822 (1983).
- Jones P , KafonekK, LauroraIet al..: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia. Am. J. Cardiol. 81, 582–587 (1998).
- Stender S , SchusterH, BarterPet al..: Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diab. Obes. Metab. 7, 430–438 (2005).
- Frick MH , EloO, HaapaKet al..: Helsinki Heart Study. N. Engl. J. Med. 317, 1237–1245 (1987).
- Rubins HB , RobinsSJ, CollinsDet al..: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL-C. N. Engl. J. Med. 341, 410–418 (1999).
- Canner PL , BergeKG, WengerNK: Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin.J. Am. Coll. Cardiol. 6,1245–1255 (1986).
- Catapano AL : Ezetimibe: A selective inhibitor of cholesterol absorption.Eur. Heart J. (Suppl. E) E6–E10 (2001).
- Fletcher SW , ColditzGA: Failure of estrogen plus progestin therapy for prevention.JAMA 288, 366–368 (2002).
- Manson JE , HsiaJ, JohnsonKCet al..: Estrogen plus progestin and the risk of coronary heart disese. N. Engl. J. Med. 349, 523–534 (2003).
- Kendall D : A phase III randomized contolled trial in type two DM patients with inadequate control on metformin comparing muraglitazar and pioglitazone. Presented at:American Diabetes Association 2005 Scientific Sessions. CA, USA June 10–14 (2005).
- Van Gaal LF , RissanenAM, ScheenAJet al..: RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study. Lancet 365, 1389–1397 (2005).
- Kashvap ML , EvansR, SimmonsPDet al..: New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well-tolerated. J. Am. Coll. Cardiol. 35(Suppl. A), 326 (2000).
- Okamoto H , YonemoriF, WakitaniKet al..: A cholesterol ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406, 203–207 (2000).
- Brousseau ME , DiffenderferMR, MillarJSet al..: Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25(5), 1057–1064 (2005).
- Brousseau ME , SchaeferEJ, WolfeMLet al..: Effects of an inhibitor of CETP on HDL-C. N. Engl. J. Med. 350(15), 1505–1515 (2004).
- Kostner K, Smith J, Dwivedy A: Lecithin-cholesterol acyltransferase activity in normocholesterolaemic and hypercholesterolaemic roosters: modulation by lipid apheresis. Eur. J. Clin. Invest. 27, 212–218 (1997).
- Cham BE , KostnerKM, ShafeyTMet al.. Plasma delipidation process induces rapid regression of atherosclerosis and mobilisation of adipose tissue. J. Clin. Apher. (2005). [Epub ahead of full print].
- Sacks F , KostnerGM, AlaupovicPet al..: Selective plasma HDL delipidation and reinfusion: a unique new approach for acute HDL therapy in the treatment of cardiovascular disease. American Heart Association Scientific Sessions (2004). Abstract 241.
- Nanjee MN , CookeCJ, GarvinRet al..: Intravenous apoA-I/lecithin discs increase pre-beta HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J. Lipid Res. 42, 1586–1593 (2001).
- Ericksson M , CarlsonLA, Miettinen T et al.: Stimulation of fecal Steroid Excretion after Infusion of Recombinant Proapolipoprotein A-I. Circulation 100, 594–598 (1999).
- Nissen SE , TsunodaT, TuzcuEMet al..: Effect of recombinant apo-AI Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292–2300 (2003).
- Navab M , AnantamaramaiahGM, Hama S et al.: Oral administration of an oral apo A-1 mimetic peptide dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105, 290–292 (2002).
- Von Eckardstein A : Therapeutic approaches for the modification of HDL.Drug Discov. Today 1, 177–187 (2004).
- Hersberger M , Von Echardstein A: Modulation of HDL-cholesterol metabolism and reverse cholesterol transport. Handbook Experimental Pharmacol. 170, 529–554 (2005).